Welcome!

Wearables Authors: Pat Romanski, Liz McMillan, Elizabeth White, Yeshim Deniz, Zakia Bouachraoui

News Feed Item

1977-2012: Science, Technology and Health Care

WHITEHOUSE STATION, N.J., Dec. 21, 2012 /PRNewswire/ -- A gallon of gas cost 62 cents, the first Star Wars opened in movie theaters and disco ruled the dance floor. But 1977 was also a milestone year in science, technology and health care.

In 1977:

  • Apple Computer Inc. is incorporated
  • The first MRI scan is performed on a human body
  • The first pneumococcal polysaccharide vaccine is approved

Science, technology and health care have evolved in many ways since 1977. For example, the pneumococcal polysaccharide vaccine that was approved in 1977 helped protect against 14 pneumococcal disease serotypes. Today, PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) helps protect against 23 serotypes, including those that can cause serious disease (pneumonia, bacteremia and meningitis) in the United States.

To view the multimedia assets associated with this release, please click; http://www.multivu.com/mnr/59521-merck-pneumovax23-pneumococcal-vaccine-polyvalent 

(Photo:  http://photos.prnewswire.com/prnh/20121221/MM26402)

While many people have owned an Apple product, seen a Star Wars movie, and gotten an MRI or know someone who has, people may not be aware of their risk for pneumococcal disease. It is also important for adults to talk with their health care professional about pneumococcal vaccination. Pneumococcus (pronounced 'noo-mo-ca-cus') is a common bacteria that can cause pneumonia, meningitis and bacteremia. These infections occur when pneumococcus invade the bloodstream, lungs or spinal fluid.

"People are more vulnerable to getting infections as they get older because their immune system is not able to respond as well as when they were younger," said John Grabenstein, Executive Director, Global Vaccine Medical Affairs & Policy at Merck. "I encourage all adults 65 and older to talk with their health care professional today about pneumococcal vaccination."

PNEUMOVAX®23 can help protect from infection by 23 forms of pneumococcal bacteria (called serotypes), including those that are most prevalent and most often cause serious disease (pneumonia, bacteremia and meningitis) in the United States.  The Centers for Disease Control and Prevention (CDC) reported that in 2008, these 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) caused 76 percent of serious pneumococcal disease in adults ages 50–64 and 66 percent of serious pneumococcal disease in adults 65 years of age and older.

About PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent)

PNEUMOVAX®23 is a vaccine that is given as a shot. It helps protect you from infection by certain germs or bacteria, which are called pneumococcus.  PNEUMOVAX®23 is for people 50 years of age and older and those 2 years of age and older who are at increased risk for infection.

Important Safety Information about PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent)

PNEUMOVAX®23 may not prevent meningitis in patients with leakage of spinal fluid caused by a cracked or injured skull or a medical operation.

PNEUMOVAX®23 may not protect everyone who gets it. It will not protect against diseases that are caused by bacteria types that are not in the vaccine.

You should not get PNEUMOVAX®23 if you are allergic to any of its ingredients, had an allergic reaction to PNEUMOVAX®23 in the past, or are less than 2 years of age.

Before getting PNEUMOVAX®23 , tell your health care professional if you or your child are allergic to the vaccine, have heart or lung problems, have a fever, have immune problems or are receiving radiation treatment or chemotherapy, are pregnant or breastfeeding.

Talk to your health care professional if you plan to get ZOSTAVAX® (zoster vaccine live) at the same time as PNEUMOVAX®23 because it may be better to get these vaccines at least 4 weeks apart.  Also talk to your health care professional if you plan to get PNEUMOVAX®23 at the same time as other vaccines.

The most common side effects of PNEUMOVAX®23 are:  pain, warmth, soreness, redness, swelling, and hardening at the injection site, headache, weakness, and feeling tired, and muscle pain. Tell your health care professional or get help right away if you have any of the following problems, which may be signs of an allergic reaction: difficulty breathing, wheezing, rash, hives.

PNEUMOVAX®23 is a vaccine recommended by the CDC to help prevent pneumococcal disease. The Advisory Committee on Immunization Practices (ACIP)—part of the CDC—recommends vaccination with PNEUMOVAX®23  for all appropriate adults 65 years of age and older, as well as people 2 and older who have medical conditions such as diabetes, cardiovascular disease and respiratory diseases like COPD that put them at higher risk for infection.  According to the CDC, adults 50 years of age and older commonly have chronic medical conditions that increase their risk for pneumococcal disease.

You can get vaccinated against pneumococcal disease at any time. Talk to your healthcare professional or pharmacist today.

Prescribing Information and Patient Information are available at http://www.merck.com/product/usa/pi_circulars/ product-specific language.pdf and http://www.merck.com/product/usa/ppi_circulars/product-specific language.pdf.

This information is provided by Merck.

About Merck

Today's Merck is a global healthcare leader working to help the world be well.  Merck is known as MSD outside the United States and Canada.  Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.  We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.  For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

CONTACT:  Andrea Johnson, +1-312-396-9708

SOURCE Merck

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

IoT & Smart Cities Stories
We are seeing a major migration of enterprises applications to the cloud. As cloud and business use of real time applications accelerate, legacy networks are no longer able to architecturally support cloud adoption and deliver the performance and security required by highly distributed enterprises. These outdated solutions have become more costly and complicated to implement, install, manage, and maintain.SD-WAN offers unlimited capabilities for accessing the benefits of the cloud and Internet. ...
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and G...
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
DXWorldEXPO LLC announced today that "IoT Now" was named media sponsor of CloudEXPO | DXWorldEXPO 2018 New York, which will take place on November 11-13, 2018 in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to great conferences, helping you discover new conferences and increase your return on investment.